154 related articles for article (PubMed ID: 12173142)
1. Doxycycline for treatment of community-acquired pneumonia.
Johnson JR
Clin Infect Dis; 2002 Sep; 35(5):632; author reply 632-3. PubMed ID: 12173142
[No Abstract] [Full Text] [Related]
2. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
5. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
Heffelfinger JD; Dowell SF; Jorgensen JH; Klugman KP; Mabry LR; Musher DM; Plouffe JF; Rakowsky A; Schuchat A; Whitney CG
Arch Intern Med; 2000 May; 160(10):1399-408. PubMed ID: 10826451
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
[TBL] [Abstract][Full Text] [Related]
7. [Choice of antibiotics in lower respiratory infections: what does pharmacodynamics bring? Clinical application of pharmacodynamic data].
Goldstein F
Presse Med; 1998 Sep; 27 Suppl 4():22-3. PubMed ID: 9798483
[No Abstract] [Full Text] [Related]
8. [Management of community-acquired pneumopathies of adults in the city and at the hospital].
Léophonte P
Presse Med; 1998 Sep; 27 Suppl 4():5-7. PubMed ID: 9798473
[No Abstract] [Full Text] [Related]
9. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
[TBL] [Abstract][Full Text] [Related]
10. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the pneumologist].
Poirier R
Presse Med; 1998 Sep; 27 Suppl 4():14-5. PubMed ID: 9798478
[No Abstract] [Full Text] [Related]
11. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.
Viasus D; Simonetti AF; Garcia-Vidal C; Niubó J; Dorca J; Carratalà J
J Antimicrob Chemother; 2017 Feb; 72(2):547-553. PubMed ID: 27798219
[TBL] [Abstract][Full Text] [Related]
12. How much evidence do we have to recommend oral doxycycline for empirical treatment of community-acquired pneumonia?
Bantar C
Clin Infect Dis; 2004 Feb; 38(3):459-60. PubMed ID: 14727226
[No Abstract] [Full Text] [Related]
13. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance and treatment of community-acquired pneumonia.
Mandell LA
Clin Chest Med; 2005 Mar; 26(1):57-64. PubMed ID: 15802166
[TBL] [Abstract][Full Text] [Related]
16. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
Lee WK; Young BW
J Antimicrob Chemother; 2005 Sep; 56(3):603-5. PubMed ID: 16040621
[No Abstract] [Full Text] [Related]
17. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the microbiologist].
Quentin C
Presse Med; 1998 Sep; 27 Suppl 4():12-3. PubMed ID: 9798477
[No Abstract] [Full Text] [Related]
18. [New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M
Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
[No Abstract] [Full Text] [Related]
19. Blood cultures for community-acquired pneumonia: No place to skimp!
Bryan CS
Chest; 1999 Nov; 116(5):1153-5. PubMed ID: 10559067
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
